

## Chemical Constituents and Pharmacological Effects of *Melilotus officinalis*- A Review

Ali Esmail Al-Snafi

Department of Pharmacology, College of Medicine, Thi qar University, Iraq.  
Received 14 January 2020; Accepted 30 January 2020

**Abstract:** *Melilotus officinalis* contained coumarins, melilotin, phenolic acids, flavonoids, steroids, saponins, volatile oils, fats, triterpenes, carbohydrates, sugar, anthraquinone glycosides, mucilage, tannin, bis hydroxycoumarin, choline, alcohols, uric acid and many other chemical groups. Antimicrobial, antioxidant, anticancer, anti-inflammatory, neural, protective, sedative, anxiolytic, smooth muscle relaxant, hypotensive and many other pharmacological effects. The current review highlighted the chemical constituents and pharmacological effects of *Melilotus officinalis*.

**Keywords:** chemical constituents, pharmacology, *Melilotus officinalis*.

### I. INTRODUCTION:

In the last few decades there has been an exponential growth in the field of herbal medicine. It is getting popularized in developing and developed countries owing to its natural origin and lesser side effects. Plants generally produce many secondary metabolites which are bio-synthetically derived from primary metabolites and constitute an important source of chemicals which are used as pharmaceuticals, agrochemicals, flavours, fragrances, colours, biopesticides and food additives<sup>(1-35)</sup>. The phytochemical analysis showed that *Melilotus officinalis* contained coumarins, melilotin, phenolic acids, flavonoids, steroids, saponins, volatile oils, fats, triterpenes, carbohydrates, sugar, anthraquinone glycosides, mucilage, tannin, bis hydroxycoumarin, choline, alcohols, uric acid and many other chemical groups. Antimicrobial, antioxidant, anticancer, anti-inflammatory, neural, protective, sedative, anxiolytic, smooth muscle relaxant, hypotensive and many other pharmacological effects. The current review will highlight the chemical constituents and pharmacological effects of *Melilotus officinalis*.

#### Plant profile:

##### Synonyms:

*Medicago officinalis*, *Melilotus arenarius*, *Melilotus arvensis*, *Melilotus melilotus-officinalis*, *Melilotus neglectus*, *Melilotus pallidus*, *Melilotus petiipierreanus*, *Trifolium melilotus*, *Trifolium melilotus-officinalis*, *Trifolium officinale*<sup>(36)</sup>.

##### Taxonomic classification:

**Kingdom:** Plantae, **Subkingdom:** Viridiplantae, **Infrakingdom:** Streptophyta, **Superdivision:** Embryophyta, **Division:** Tracheophyta, **Subdivision:** Spermatophytina, **Class:** Magnoliopsida, **Superorder:** Rosanae, **Order:** Fabales, **Family:** Fabaceae, **Genus:** *Melilotus*, **Species:** *Melilotus officinalis*<sup>(37)</sup>.

##### Common names:

**Arabic:** Nafal; Melesa, Hahaq, Handikok hakli, Ghsin El-ban; **Canada:** Yellow sweet clover; **Chinese:** cao mu xi; **Cuba:** Torongil For; **English:** common melilot, field melilot, ribbed melilot, yellow melilot, yellow sweetclover, yellow sweet-clover; yellow trefoil; **French:** melilot des champs, melilot jaune, melilot officinal; **Germany:** Acker- Honigklee, Echter Steinklee, gelber Steinklee; **Italy:** meliloto giallo; **Japan:** seiyō-ebirahagi; **Netherlands:** Akkerhoningklaver; **Portugal:** trevo-cheiroso; **Spanish:** cornilla real, meliloto Amarillo, meliloto de los campos, trébol de olor, trebol de olor amarillo; **Sweden:** Gulmelot<sup>(38-39)</sup>.

##### Distribution:

It was distributed in **Africa** (Egypt, Libya, South Africa); **Asia** (Oman, Saudi Arabia, Qatar, United Arab Emirates, Yemen, Afghanistan, Cyprus, Iran, Iraq, Palestine, Jordan, Lebanon, Turkey, Armenia, Azerbaijan, Georgia, Russian federation, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Bhutan, India, Pakistan, Myanmar), **Europe** (Austria, Czechoslovakia, Germany, Hungary, Poland, Belarus, Estonia, Latvia, Lithuania, Moldova, Russian Federation-European part, Albania, Bulgaria, Former Yugoslavia, Greece, United Kingdom, Italy, Romania, France, Spain), **Australasia** (Australia, New

Zealand), **Northern America** (United states and Canada) and **Southern America** (Argentina, Chile, Bolivia, Paraguay, Uruguay)<sup>(38)</sup>.

**Description:**

It is annual to biennial, erect or decumbent plant. Stems erect, 40-100(-250) cm, longitudinally ridged. Stipules linear-falcate, 3-5(-7) mm, entire or with 1 tooth at base; petiole slender; leaflets obovate, broadly ovate, oblanceolate, to linear, 15-25(-30) × 5-15 mm, lateral veins running into teeth, 8-12 pairs, margins shallowly serrate. Racemes 6-15(-20) mm, 30-70-flowered, dense at first, becoming lax in anthesis; bracts equal to pedicels, 1.5-2 mm. Corolla yellow, 4.5-7 mm; standard ± equal to wings and keel. Ovary narrowly ovate; ovules (4-)6(-8). Legume ovoid, 3-5 × ca. 2 mm, veins transversely reticulate, dark brown, apex with persistent style. Seeds 1 or 2, yellowish brown, ovoid, ca. 2.5 mm, smooth<sup>(40-41)</sup>.

**Traditional uses:**

The plant was used as aromatic, emollient, demulcent, maturant, tonic, aphrodisiac, carminative to relieve flatulence and externally applied as poultice for pains and aches. The small fruits were used as demulcent, maturant, tonic, aphrodisiac and in leucoderma<sup>(42)</sup>.

Herbal tea was used as a wash and rinse for swelling and swollen glands, abscesses, and swelling of the lymph nodes. Tea herbs, or the flowers themselves, were applied in cases of cold, mucosity, and respiratory and gastrointestinal disorders<sup>(43)</sup>.

It was also used in idiopathic headaches, long-standing neuralgias, coldness, tenderness, lameness or marked soreness of joints, cold, menstrual colic, ovarian neuralgia, colic with diarrhoea and much<sup>(44)</sup>.

**Parts used medicinally:**

The whole herb and flowering shoots and fruits were used medicinally<sup>(45)</sup>.

**Physicochemical parameters:**

Physicochemical parameters of powdered *Melilotus officinalis* (% w/w) were: total ash: 11.25±0.25, acid insoluble: 2.11±0.12, water soluble: 6.86±0.19, methanol extractive value 3.96, aqueous extractive value 13.27, volatile oil 0.59±0.02 and loss on drying 6.69±0.12<sup>(46)</sup>.

**Chemical constituents:**

The preliminary phytochemical analysis showed that *Melilotus officinalis* contained coumarins, melilotin, phenolic acids, flavonoids, steroids, saponins, volatile oils, fats, triterpenes, carbohydrates, sugar, anthraquinone glycosides, mucilage, tannin, bis hydroxycoumarin, choline, alcohols and uric acid<sup>(46-50)</sup>.

The dominant components in total lipophilic compounds of the chloroform extract of *Melilotus officinalis* were 1,3- di-o-methylmyo-inositol (75.503%), acetal (5.874%), palmitic acid (2.252%) and linoleic acid (1.958%)<sup>(51)</sup>.

Twenty six constituents were identified in the *Melilotus officinalis* essential oil from Borispol (Ukraine), hexahydrofarnesylacetone (16.64%), β-eudesmol (11.49%) and globulol (8.65%) represented the main constituents. However, the identified compounds and their percentage were: para-hydroxybenzaldehyde 1.96, camphor 3.15, terpinene-4-ol 4.17, 2-methylbenzaldehyde 2.70, aromadendrene 1.38, geranylacetone 1.21, 2,6,10-trimethyldodecane (farnesane) 5.68, β-ionone 0.93, β-ionone-5,6-epoxide 2.08, epi-globulol 3.05, isophytol 1.47, spathulenol 4.27, globulol 8.65, viridiflorol 2.98, epi-eudesmol 2.50, γ-eudesmol 1.98, β-eudesmol 11.49, bisabolon oxide 7.43, hexahydrofarnesylacetone 16.64, methyl palmitate 2.68, methyl linoleate 1.77, methyl linolenate 5.19, phytol 4.52, ethyl linoleate 0.96 and Phytol acetate 1.12%<sup>(52)</sup>.

The main compounds identified in the volatile oils of the methanol extract of the leaves of *Melilotus officinalis* from Syria were: n-docosane (39.82%), hydrocoumarin (15.39%) and methyl 3-(2-hydroxyphenyl) propionate (14.29%), while, the main compounds identified in the volatile oils of the hexane extract of the leaves of *Melilotus officinalis* from Syria were: palatinol (17.77%), 9,12,15-octadecatrienoic acid, methyl ester (12.85%), 1-(dimethylamino)-5-[(4'-ethynylphenyl) ethynyl] naphthalene (12.59%), 2,4-dioctylphenol (9.73%), hexadecanoic acid, methyl ester (8.99%) and ecosane(8.53%)<sup>(53)</sup>.

Hexadecanoic acid, lupanone, lupeol, betulinic acid, oleanolic acid, kaempferol-3-O-β-glucopyranoside were isolated from the methanol extract of whole *Melilotus officinalis*<sup>(50)</sup>.

Oleanene glucuronide (melilotus-saponin O1), together with soyasaponin, dehydrosoyasaponin, acetyl-soyasaponin were isolated from the roots of *Melilotus officinalis*<sup>(54)</sup>, while, soyasapogenols B and E were isolated from the aerial parts<sup>(55)</sup>.

P-hydroxybenzoic acid glycosides [p-hydroxybenzoic acid-4-O-α-D-manopyranosyl-(1→3)-α-L-rhamnopyranoside and -O-α-L-rhamnopyranosyl-(1→6)-α-D-mano pyranosyl -(1 → 3)-α-L-rhamnopyranoside], salicylic acid, coumarin, betaine, fumaric acid, caffeic acid, luteolin, quercetin were isolated from the 70% ethanol extract of of the aerial parts of *Melilotus officinalis*<sup>(56)</sup>.

Coumarin concentration in whole *Melilotus officinalis* hexane extract was  $8.86 \pm 0.67$  mg/100 g, in ethanol 96% extract  $316.37 \pm 8.10$  mg/100 g, and in ethanol 50% extract  $146.43 \pm 9.15$  mg/100 g<sup>(57)</sup>.

HPLC analysis revealed that five grams of the flower powder contained 9.7 mg gallic acid, 99 mg catechin, 21.9 mg caffeic acid, 0.86 mg chlorogenic acid, 1.13 mg quercetin, 548.9 mg cinnamic acid, 289 mg coumarin and 126 mg p-coumaric acid<sup>(58)</sup>.

The concentrations of total phenols (mg RU/g extract), flavonoids (mgGA/g extract), tannins (mgGA/g extract) and proanthocyanidins (CChE/g extract) in *M. officinalis* aerial parts were ( $19.66 \pm 0.23$ ,  $36.25 \pm 0.79$ ,  $21.25 \pm 1.32$  and undetected, respectively, in the water extract), ( $53.09 \pm 1.67$ ,  $27.12 \pm 0.49$ ,  $11.87 \pm 0.12$  and  $3.77 \pm 0.03$ , respectively, in the acetone extract) ( $33.52 \pm 0.22$ ,  $16.37 \pm 0.59$ ,  $6.12 \pm 0.16$  and  $1 \pm 0.13$ , respectively, in the diethyl ether extract) and ( $34.19 \pm 0.06$ ,  $21.37 \pm 1.09$ ,  $1.37 \pm 1.08$  and  $0.77 \pm 0.59$ , respectively, in the ethanol extract)<sup>(59)</sup>.

However, the total phenolic concentration in whole *Melilotus officinalis* hexane extract was:  $10.5 \pm 0.6$  mg gallic acid equivalent/ g, in ethanol 96% extract:  $47.1 \pm 3.6$  mg gallic acid equivalent/ g, and in ethanol 50% extract:  $46.3 \pm 7.4$  mg gallic acid equivalent/ g<sup>(57)</sup>.

The plant contained many flavonoids included: robinin, rutin, kaempferol-3-O- $\beta$ -glycopyranoside and kaempferol-7-O-glycosides<sup>(60-61)</sup>.

### **Pharmacological effects:**

#### **Antimicrobial effect:**

The antimicrobial effect of the methanolic extract of *Melilotus officinalis* was investigated against Gram positive and Gram negative bacteria. MIC against *Escherichia coli*: 15mg, *Klebsiella pneumonia*: 18mg, *Proteus mirabilis*: 20mg, *Pseudomonas aeruginosa*: 25mg, *Staphylococcus aureus*: 25mg, *Streptococcus pyogenes*: 30mg, *Bacillus subtilis*: 25mg, *Bacillus cereus*: 25 mg and *Candida albicans* 35mg<sup>(33)</sup>.

The antibacterial activity of the water, acetone, diethyl ether and ethanol extracts of *Melilotus officinalis* was studied against *Klebsiella pneumonia*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Proteus mirabilis*, *Salmonella typhimurium*, *Salmonella enteric*, *Enterococcus faecalis*, *Staphylococcus aureus*, *Sarcina lutea*, *Bacillus subtilis*, *Bacillus cereus*, *Bifidobacterium animalis* subsp. *lactis* and *Lactobacillus rhamnosus*. The values of MIC and MMC were in a range of  $<0.156$  mg/ml to  $>20$  mg/ml. The intensity of antibacterial activity depended on the type of extract and the type of bacteria. The extracts were active in the following ascending order: water  $<$  ethanol  $<$  diethyl ether  $<$  acetone. The acetone and the diethyl ether were the most active extracts, while water and ethanol extracts showed significantly lower activity. Gram negative bacteria showed higher sensitivity to the acetone and diethyl ether extracts, but never in concentrations less than 10 mg/ml for MIC and MMC, except for *Escherichia coli* which was sensitive in the concentration of 5 mg/ml of the ether extract for MIC<sup>(59)</sup>.

The antibacterial effect of the aqueous, methanolic and ethanolic extract of *Melilotus officinalis* was investigated against Gram negative bacteria (*Escherichia coli*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Serratia marcescens*, *Proteus vulgaris*, *Enterobacter cloacae* and *Klebsiella pneumonia*) and Gram positive bacteria (*Streptococcus pyogenes*, *Staphylococcus aureus* and *Staphylococcus epidermidis*). The ethanolic extract of *Melilotus officinalis* showed more antibacterial effect than aqueous and methanolic extracts against *S. marcescens* and *S. typhimurium*. *P. vulgaris*, *E. cloacae*, and *E. coli* were susceptible to aqueous extract of *Melilotus officinalis*. However, all the tested bacteria were not susceptible to methanolic extracts<sup>(62)</sup>.

*In vitro* antifungal activities of *Melilotus officinalis* extracts were evaluated against *C. inconspicua*, *C. guilliermondii*, *C. albicans*, *C. krusei*, *C. lusitaniae*, *C. glabrata*, *C. parapsilosis*, *C. methapsilosis*, and *C. ortopsilosis*. The results showed that *Melilotus officinalis* extracts were active antimycotic agents against wide range of *Candida* species. *C. guilliermondii* and *C. parapsilosis* were the most sensitive<sup>(63)</sup>.

The antifungal activity of *Melilotus officinalis* was studied against *Microsporium canis*, *Trichophyton mentagrophytes* var. *interdigitale*, *Trichophyton mentagrophytes* var. *mentagrophytes*, *Trichophyton rubrum* and *Trichophyton violaceum*. It caused partial growth inhibition at 0.5% and 0.25% concentration of ethanol extract. It appeared that *Trichophyton mentagrophytes* was the more sensitive fungi<sup>(64)</sup>.

The anti-candidal effect of ethanol (30%v/v) *Melilotus officinalis* extracts was studied *in vitro*. *Melilotus officinalis* extract possessed potent anti-candidal activity with minimum inhibitory concentration of 19.3 mg/ml against *C. norvegica*, *C. pulcherrima* and *C. guilliermondii*<sup>(65)</sup>.

The therapeutic activity of coumarinic extract of *Melilotus officinalis* was studied clinically in fourteen patients with chronic upper arm lymphedema due to post-lymphadenectomy of the axilla for breast cancer. Patients were receive 400 mg of coumarinic extract containing 8 mg of coumarine in a sole daily administration for 6 months. Of the fourteen treated patients, 11 patients (52.3%) showed reduction of the circumference of the affected arm of 5% with respect to base values. Three patients (14.2%) had no change. In 12 patients (57.1%), the symptoms were improved. Regarding tolerability: 3 patients (14.2%) had transitory

gastrointestinal side effects. The authors concluded that cumarinic extract of *Melilotus officinalis* was effective in reducing lymphedema in 79% of the patients treated for a period of six months<sup>(66)</sup>.

#### **Dermatological effect:**

In studying the beneficial effect of the extract of *Melilotus officinalis* in skin care applications, the extract showed an ability of stimulating skin cells and promoting tissue regeneration, preventing skin aging, and reducing fat deposition. The effects of ethanolic extract at doses ranging from 0.25 to 50 µg/ml (from 1 to 5000 µg/ml in cell viability assays) were evaluated using *in vitro* tests on HaCaT human keratinocytes, 46BR 1N fibroblasts, and adipocyte cell cultures, and on matrix-degrading enzymes. MTT assay revealed weak effects on cell viability ( $IC_{50} > 1000$  µg/ml) and significant increase of fibroblast growth rate. Cell-free enzymatic assays showed collagenase inhibition, while an ELISA assay revealed efficient stimulation of fibroblast collagen production. Oil-Red-O adipocyte staining showed pronounced lipolytic effect<sup>(67)</sup>.

The effects of *Melilotus officinalis* ointment in the healing of burn wounds were studied in burn ulcers produced on the back of rats. Wound healing contraction and histopathological examination were evaluated at the end of 7, 14, and 21 days. *Melilotus officinalis* preparations significantly improved the quality of wound healing and scar formation and also they were more appropriate treatment choices than silver sulfadiazine<sup>(68)</sup>.

The effect of melilotus extract on the thermal edema was studied in rats. The intraperitoneal injection of melilotus extract immediately after burn greatly reduced the amount of swelling and effectively inhibited the occurrence of necrosis and induration in the injured leg-skin as compared with the saline controls in which a 3<sup>rd</sup> degree of thermal injury was observed. Intraperitoneal or subcutaneous local injection of melilotus extract, 4 hr before burn was effective in reducing the edema and thermal injury. No increase of the lymph flow and output of lymphocytes and protein from the thoracic duct lymph was observed in thermally injured rats given an injection of melilotus extract. Massive infiltration of neutrophils and macrophages 6 to 24 hr after the subcutaneous injection of melilotus extract was histologically observed in the dermal lesion of normal rats. Twenty-four hr later, macrophages, fibroblasts, and lymphocytes became predominant<sup>(69)</sup>.

#### **Hypotensive effect:**

*Melilotus officinalis* extract caused hypotensive and vaso-dilating actions due to the vascular smooth muscle relaxation in rabbits<sup>(70)</sup>.

The hypotensive effect of *Melilotus officinalis* butanolic fraction (20-100 mg/kg, iv) was investigated in anaesthetized normotensive rats. The doses of 20 and 40 mg/kg iv, produced non-significant reduction in the blood pressure, but 60, 80 and 100 mg/kg, iv, significantly ( $p < 0.05$ ) decreased blood pressure<sup>(71)</sup>.

#### **Antioxidant effect:**

The antiradical activity of the whole *Melilotus officinalis* hexane, 96 and 50% ethanol extracts was determined using DPPH. Their DPPH scavenging activity was  $9.0 \pm 0.28$ ,  $35.6 \pm 0.65$  and  $30.2 \pm 0.98\%$  respectively<sup>(22)</sup>. The free radical scavenging activity of *Melilotus officinalis* was studied using DPPH assay at different temperatures. The results demonstrated that with increasing temperature, the free radical scavenging activity was decreased, it gave the highest free radical scavenging activity at 25°C<sup>(72)</sup>.

The antioxidant activity of the water, acetone, diethyl ether and ethanol extracts of *Melilotus officinalis* was studied using DPPH method. The water extract demonstrated antioxidant activity in the range of 21.43 to 93.59% %; acetone extract 11.72 to 67.95%, diethyl ether extract 17.94 to 61.28% and ethanol extract 13 to 71.98%. The extent of reducing power in the examined extracts was various. The highest activity was detected with the water extract, while the lowest reducing power was demonstrated in the diethyl ether extract<sup>(59)</sup>.

Nine compounds (2 p-hydroxybenzoic acid glycosides, 3 acid components, 2 flavonoids, 1 coumarin and 1 alkaloid) isolated from the 70% ethanol aqueous extract of the aerial parts of *Melilotus officinalis* were tested for antioxidant activity using ABTS and DPPH. The results showed that [p-hydroxybenzoic acid-4-O- $\alpha$ -D-manopyranosyl-(1  $\rightarrow$ 3)- $\alpha$ -L-rhamnopyranoside 4-O- $\alpha$ -L-rhamnopyranosyl-(1  $\rightarrow$ 6)- $\alpha$ -D-manopyranosyl-(1  $\rightarrow$ 3)- $\alpha$ -L-rhamnopyranoside, caffeic acid, luteolin and quercetin] exhibited better antioxidant activity than other compounds<sup>(56)</sup>.

The antioxidant and anti-inflammatory effects of the aqueous extract of *Melilotus officinalis* were studied in the acetic acid induced ulcerative colitis in rats. The FRAP value of the extract was  $2.91 \pm 0.14$  µM/g. There were significant differences between the groups of rats which received the gel or aqueous extract of the flower compared to the negative control group using normal saline and the base gel, and they had no significant differences with the positive control group using the Asacol, regarding the pathologic, malondialdehyde, and weight improvements<sup>(23)</sup>. The antioxidant effect of *Melilotus officinalis* aqueous extracts (1000 and 2000 mg/kg bw, orally, for seven days) was studied in colitis induced by intra-rectal acetic acid (3% v/v) in rats. Treatment with *Melilotus officinalis* aqueous extract enhanced colonic antioxidant capacity and

decreased inflammation and acute colonic injury induced by acetic acid, dose-dependent. Furthermore, the extract significantly ( $p \leq 0.05$ ) reduced the colonic level of malondialdehyde and myeloperoxidase, and significantly ( $p \leq 0.05$ ) increased the level of reduced glutathione ( $p \leq 0.05$ ). The extract possessed more effects at the dose of 2000 mg/kg than 1000 mg/kg dosage and prednisolone<sup>(73)</sup>.

The interference of *Melilotus officinalis* leaves extract with ROS and RNS during the course of human PMN respiratory bursts was studied, the lowest concentration at which it still has antioxidant activity by means of luminol amplified chemiluminescence (LACL) and the ability to counteract lipid peroxidation (LPO) in human cells, were also studied. The extract of *Melilotus officinalis* exerted its anti-ROS/RNS activity in a concentration dependent manner, with significant effects being observed for even very low concentration: 20 µg/ml without L-arginine and 10 µg/ml when L-arginine was added to the formyl-methionyl-leucylphenylalanine (fMLP) test. LPO assay confirmed these results, which were paralleled by the electron paramagnetic resonance study<sup>(74)</sup>.

#### **Hepatoprotective effect:**

The hepatoprotective effect of methanolic extract of *Melilotus officinalis* (50 mg/kg and 100 mg/kg) was investigated against paracetamol and carbon tetrachloride induced hepatic damage in mice. *Melilotus officinalis* extract showed significant hepatoprotective effects by decreasing the levels of serum markers (total bilirubin, SGOT, SGPT, ALP, albumin and total protein). These effects were further documented by histopathological studies<sup>(75)</sup>.

The hepatoprotective and antioxidant potentials of *Melilotus officinalis* was investigated in hepatotoxicity induced by iron dextran (12.5 mg/100g) in rats. Different fractions of *Melilotus officinalis* were given orally for 30 days. Biochemical parameters were estimated on 15<sup>th</sup> and 30<sup>th</sup> day whereas antioxidant parameters on 30<sup>th</sup> day of treatment. Methanolic fraction of methanolic extract and methanolic fraction of aqueous extract of *Melilotus officinalis* significantly ( $p < 0.01$ ) decreased superoxide dismutase, catalase, glutathione, while, increases malondialdehyde as compared to untreated rats<sup>(76)</sup>.

#### **Neuroprotective effect:**

The protective effect of *Melilotus officinalis* extract (100, 250 and 500 mg/kg, for 3 days) on the brain tissues in acute cerebral ischemia induced by occlusion of carotid artery, was studied in rats. Cerebral ischemia was confirmed by estimation of infarct volume and neurological deficit score, in addition to plasma biochemical parameters such as 6-keto-PGF1 $\alpha$  and TXB2 and concentration of cytokine, oxidative stress, apoptosis ratio and protein expressions of Bcl2 & Bax in the brain tissues. The extract significantly ( $p < 0.01$ ) decreased the infarct volume and neurological deficit score compared with negative control group. It also significantly ( $p < 0.01$ ) decreased oxidative stress and cytokine in the brain tissues and increased plasma concentration of 6-keto-PGF1 $\alpha$ . Plasma concentration of TXB 2 was significantly enhanced by the extract. Extract was also ameliorated the apoptosis induced by cerebral ischemia<sup>(77)</sup>.

#### **Sedative and anxiolytic effects:**

The sedative effect of *Melilotus officinalis* extract was evaluated using a model of prolongation of hypnotic time of pentobarbital sodium in mice. Sedative action was recognized markedly in mice treated by the extract<sup>(70)</sup>.

The antianxiety effect of petroleum ether, chloroform, ethanol, and water extracts (50, 100, and 200 mg/kg, po) of roots and aerial parts of *Melilotus officinalis* was studied in mice, using elevated plus maze (EPM) and mirror-chamber models of anxiety. The ethanol extract prepared from aerial parts at 100 and 200 mg/kg showed a significant anxiolytic effect as compared to control and standard treatment group. The petroleum ether, chloroform, and water extracts (50, 100, and 200 mg/kg) of the aerial parts of the plant did not produce antianxiety effect<sup>(78)</sup>.

#### **For the treatment of Alzheimer Disease:**

The effect of *Melilotus officinalis* extract in Alzheimer disease was studied, regarding its possible role as anti-inflammatory, anti-oxidant agent and its effect on the expression of many genes including *DAXX*, *NFkB* and *VEGF*. The results revealed that the extract caused significant decreased the expression of *Daxx*, *Nfkb* and *Vegf* genes in the sporadic Alzheimer disease rat's model compared to the streptozotocin (STZ)-induced rats. Furthermore, no significant changes were seen in swimming distance and time for finding the hidden platform in the extract- treated compared to the STZ-induced group. No significant changes were observed in the memory level among treated and untreated groups<sup>(79)</sup>.

**Smooth muscle relaxant effect:**

*Melilotus officinalis* flowers and leaves extract caused relaxing action on the isolated ileum in mice and antagonized barium chloride induced contraction of the ileum<sup>(70)</sup>.

**Management of iron overload:**

The beneficial effects of different fractions of *Melilotus officinalis* in management of iron overload disease and its complications (free radicals generation and organ damage) were studied in rats. Iron overload was induced by 6 ip, injections of iron dextran (12.5 mg/100 g) over the period of 30 days. The different fractions of *Melilotus officinalis* were given orally for 30 days. The iron chelating and various biochemical parameters were estimated on 15<sup>th</sup> and 30<sup>th</sup> day. Methanolic fraction of methanolic extract and methanolic fraction of aqueous extract of *Melilotus officinalis* caused significant (p<0.01) iron chelating potential and significant (p<0.01) antioxidant effects in rats. Better iron chelation was observed on 30<sup>th</sup> day and at higher dose (300 mg/kg) as compared to 15<sup>th</sup> day and at lower dose (150 mg/kg)<sup>(80)</sup>.

**Anticoagulant effect:**

The anticoagulation effect of crude coumarin extract of yellow clover *Melilotus officinalis* was investigated by prothrombin time, it showed concentration dependent anticoagulation activity<sup>(81)</sup>.

**Antiinflammatory effect:**

The anti-inflammatory effect of *Melilotus officinalis* extract was recorded in mice<sup>(70)</sup>. Nine compounds (2 p-hydroxybenzoic acid glycosides, 3 acid components, 2 flavonoids, 1 coumarin and 1 alkaloid) isolated from the 70% ethanol aqueous extract of the aerial parts of *Melilotus officinalis* were tested for anti-inflammatory effects in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. All compounds inhibited LPS-induced nitric oxide (NO) and prostaglandin E2 production by suppressing the expression of inducible NO synthase (iNOS) and cyclooxygenase-2, in LPS-stimulated RAW 264.7 cells<sup>(56)</sup>.

The effect of *Melilotus officinalis* extract (contained 0.25% coumarin), on acute inflammation induced by oil of turpentine was investigated in male rabbits. The effects were evaluated by measuring serum citrulline, a test of *in vitro* phagocytosis, total leukocyte count and differential leukocyte count. *Melilotus officinalis* possessed antiinflammatory effects, it reduced the activation of circulating phagocytes and lowered citrulline production similar to hydrocortisone sodium hemisuccinate and coumarin. In the bone marrow acute phase response, *Melilotus officinalis* had an inhibitory action that was lower than that of hydrocortisone sodium hemisuccinate and similar to coumarin<sup>(82)</sup>.

The mechanisms by which melilotus extract interferes with inflammation-associated and oxidative stress pathways during sepsis were investigated in cecal ligation- perforation (CLP)- induced sepsis in mice. Melilotus extract possessed marked effect on the pathological manifestation of lung tissue and lung inflammatory response, it up regulated TIPE2, heme oxygenase-1 and IκB expression, and inhibited TLR4 and NF-κB activities. In addition, melilotus extract, treated mice showed decreased levels of MPO and MDA as well as increased levels of SOD<sup>(83)</sup>.

**Antidiabetic effect:**

The therapeutic efficacy of oral use of a combination of [desmin (300 mg/day) and troxerutin (300 mg/day) with *Centella asiatica* (30 mg/die) and *Melilotus officinalis* (160 mg/die) for 14 months] was evaluated in diabetic patients with diabetic cystoid macular edema without macular thickening. The orally administered combination preserved retinal sensitivity in diabetic patients<sup>(84)</sup>.

*Melilotus officinalis* was introduced as a component of a new drug by trade name of Semilil (Angipars). The effects of Angipars (ip, 5, 10, and 20mg/kg for 2 weeks) on nerve conduction velocity, histological alterations, and behavioral indices were investigated in streptozotocin (STZ) induced diabetic rats. Intraperitoneal injection of Angipars, significantly improved nerve conduction velocity in neuropathic rats. It also reduced the physiologic symptoms and improved sciatic morphological injuries in neuropathic rats<sup>(85)</sup>.

Furthermore, the investigations also revealed that Semilil (Angipars) was safe with therapeutic efficacy in focal cerebral ischemia in rats, wound healing in rodents, human diabetic foot ulcer and pressure ulcers<sup>(86-89)</sup>.

**Management of venous insufficiency:**

The therapeutic efficacy and the clinical tolerability of an association of alphatocopherol, rutin, *Melilotus officinalis*, and *Centella asiatica* was evaluated in patients with chronic venous insufficiency after 15 and 30 days treatment. A significant improvement of the clinical symptomatology was obtained, characterised by a diminution of the soprafascial edema after the treatment period<sup>(90)</sup>.

**Antitumor effect:**

The antitumor activity of the aqueous, methanolic and ethanolic extract of *Melilotus officinalis* were investigated with *Agrobacterium tumefaciens*-induced potato disk tumor assay. Methanolic and ethanolic extract caused 33.8, 5.0 and 20.0% tumor growth inhibition respectively<sup>(62)</sup>.

**Toxicity and side effects:**

During the process of spoiling, the coumarins in sweet clover are converted to toxic dicumarol, a potent vitamin K antagonist and anticoagulant. Any method of hay storage that allows molding of sweet clover promotes the likelihood of formation of dicumarol in the hay. When toxic hay or silage is consumed for several weeks, dicumarol alters proenzymes required for synthesis of prothrombin, resulting in hypoprothrombinemia (by preventing formation of the active enzyme). It probably also interferes with synthesis of factor VII and other vitamin K-dependent coagulation factors. Dicumarol concentrations of 20–30 mg/kg of hay ingested throughout several weeks are usually required to cause poisoning in cattle. However, all species of animals are susceptible, it mostly occurred in cattle, to a limited extent in pigs, and horses, while sheep are quite resistant. The time between consumption of toxic sweet clover and appearance of clinical disease varies greatly and depends on the dicumarol content of the particular sweet clover variety being fed, age of the animals, and amount of feed consumed. If the dicumarol content of the ration is low or variable, animals may consume it for months before signs of disease appear. Hay containing dicoumarol levels of 10-20 mg/kg of feed can be fed for 100 days before poisoning develops. Feeds containing 60-70 mg/kg of feed can cause poisoning in 21 days. The first indication of dicumarol poisoning in cattle, may be the death of one or more animals. In intoxicated animals, the first signs may be stiffness and lameness, due to bleeding into the muscles and joints. Cardiovascular signs (severe hemorrhaging will cause anemia, pale mucous membranes, rapid heart rate and death), respiratory signs (epistaxis), renal signs (hematuria), reproductive signs (excessive hemorrhaging during calving) and ocular signs (hemorrhaging into the anterior chamber of the eye). Death is generally caused by massive hemorrhage or bleeding. In horses poisoning manifested by excessive blood loss, pale mucous membranes and weakness. Prothrombin times above 40 seconds are suggestive of decreased clotting ability. Blood prothrombin, activated partial thromboplastin times, and clotting times are markedly increased<sup>(91-94)</sup>.

**REFERENCES:**

- [1]. Al-Snafi AE. Pharmacological and toxicological effects of *Heliotropium undulatum* (*H. bacciferum*) and *Heliotropium europaeum*- A review. Indo Am J P Sc 2018; 5 (4): 2150-2158.
- [2]. Al-Snafi AE. Study the efficacy of anti-estrogenic drugs in the treatment of poly cystic ovary induced in female rats by estrogen valerate. World J Pharm Sci 2014; 2(4): 313-316.
- [3]. Al-Snafi AE. A review on pharmacological activities of *Kochia scoparia*. Indo Am J P Sc 2018; 5 (4): 2213-2221.
- [4]. Al-Snafi AE. Medicinal plants affected contractility of smooth muscles- A review . IOSR Journal of Pharmacy 2018; 8(11): 22-35.
- [5]. Al-Snafi AE. Fritillaria imperialis- A review. IOSR Journal of pharmacy 2019, 9(3): 47-51.
- [6]. Al-Snafi AE. Constituents and pharmacology of *Geum urbanum*- A review. IOSR Journal of pharmacy 2019; 9(5): 28-33.
- [7]. Al-Snafi AE. Medical importance of *Glossostemon bruguieri* – A review. IOSR Journal of pharmacy 2019; 9(5): 34-39.
- [8]. Al-Snafi AE. The medical benefit of *Gnaphalium luteoalbum*-A review. IOSR Journal of pharmacy 2019; 9(5): 40-44.
- [9]. Al-Snafi AE. Molecular mechanisms of the antimicrobial effect of natural flavonoids against human pathogens. In: Recent advances in the molecular mechanism of flavonoids. Edited by K. Pandima Devi, Studium press, India, 2018.
- [10]. Al-Snafi AE. Chemical constituents and pharmacological effects of *Lythrum salicaria* - A review. IOSR Journal of Pharmacy 2019; 9(6): 51-59.
- [11]. Al-Snafi AE. Medical benefit of *Malva neglecta* - A review. IOSR Journal of Pharmacy 2019; 9(6): 60-67.
- [12]. Al-Snafi AE. A review on *Lagerstroemia indica*: A potential medicinal plant. IOSR Journal of Pharmacy 2019; 9(6): 36-42.
- [13]. Al-Snafi AE. Pharmacological and Therapeutic effects of *Lallemantia royleana*- A review. IOSR Journal of Pharmacy 2019; 9(6):43-50.
- [14]. Al-Snafi AE. Chemical constituents and pharmacological effects of *Lathyrus sativus*- A review. IOSR Journal of Pharmacy 2019; 9(6): 51-58.
- [15]. Al-Snai AE. Iraqi medicinal plants with antifungal effect- A review. IOSR Journal of Pharmacy 2019; 9(7): 16-56.

- [16]. Al-Snai AE. Iraqi medicinal plants with antiviral effect- A review. IOSR Journal of Pharmacy 2019; 9(7): 57-75.
- [17]. Al-Snai AE. A review on *Lycopus europaeus*: A potential medicinal plant. IOSR Journal of Pharmacy 2019; 9(7): 80-88.
- [18]. Al-Snai AE. *Lemna minor*: Traditional uses, chemical constituents and pharmacological effects- A review. IOSR Journal of Pharmacy 2019; 9(8): 6-11.
- [19]. Al-Snai AE. Chemical constituents and pharmacological effects of *Lithospermum officinale*. IOSR Journal of Pharmacy 2019; 9(8): 12-21.
- [20]. Al-Snai AE. Iraqi medicinal plants with antibacterial effect- A review. IOSR Journal of Pharmacy 2019; 9(8): 22-103.
- [21]. Al-Snai AE, Talab TA. A review of medicinal plants with nephroprotective effects. GSC Biological and Pharmaceutical Sciences 2019; 8(1): 114-122.
- [22]. Al-Snai AE, Al-Kamel ML, Esmael ME. Antifungal effect of *Alhagi maurorum* phenolic extract. IOSR Journal of Pharmacy 2019; 9(8): 7-14.
- [23]. Al-Snai AE. Pharmacological and therapeutic effects of *Lippia nodiflora* (*Phyla nodiflora*). IOSR Journal of Pharmacy 2019; 9(8):15-25.
- [24]. Al-Snai AE, Mousa HM, Majid WJ. Medicinal plants possessed hepatoprotective activity. IOSR Journal of Pharmacy 2019; 9(8): 26-56.
- [25]. Al-Snafi AE. Medical benefit of *Lallemantia iberica*- A review. To Chemistry Journal 2019; 3: 97-102.
- [26]. Al-Snafi AE. Constituents and pharmacological effects of *Leontice leontopetalum*- A review. To Chemistry Journal 2019; 3: 103-108.
- [27]. 267-Al-Snafi AE. Constituents and pharmacological effects of *Leontice leontopetalum*- A review. To Chemistry Journal 2019; 3: 103-108.
- [28]. 268-Al-Kamel ML and Al-Snafi AE. Antibacterial effect of the phenolic extract of *Alhagi maurorum*. IOSR Journal of Pharmacy 2019; 9(9):47-55.
- [29]. 269-Al-Snafi AE. A review on *Luffa acutangula*: A potential medicinal plant. IOSR Journal of Pharmacy 2019; 9(9):56-67.
- [30]. 270-Al-Snafi AE. Constituents and pharmacology of *Luffa cylindrica*- A review. IOSR Journal of Pharmacy 2019; 9(9):68-79.
- [31]. 271- Al-Snafi AE. A review on *Lawsonia inermis*: A potential medicinal plant. International Journal of Current Pharmaceutical Research 2019; 11(5):1-13.
- [32]. 272- Al-Snafi AE. Medicinal value of *Lagerstroemia speciosa*: An updated review. International Journal of Current Pharmaceutical Research 2019; 11(5):18-26.
- [33]. 273- Salehi B, Krochmal-Marczak B, Skiba D, Patra JK, Das SK Das G, Popović- Djordjević JB, Kostić AZ, Kumar NV, Tripathi A, Al-Snafi AE, Arserim-Uçar DK, Kononov DA, Csopor D, Shukla I, Azmi L, Mishra AP, Sharifi-Rad J, Sawicka B, Martins N, Taheri Y, Fokou BVT, Capasso R and Martorell M. *Convolvulus* plant- A comprehensive review from phytochemical composition to pharmacy. Phytotherapy Research 2019;1-14.
- [34]. 274- Al-Snafi AE. Chemical constituents and pharmacological activities of *Lantana camara*- A review. Asian J Pharm Clin Res 2019; 12(12):10-20.
- [35]. 275-Al-Snafi AE. Chemical constituents and pharmacological effects of *Lepidium sativum*- A review. International Journal of Current Pharmaceutical Research 2019; 11(6):1-10.
- [36]. The plant list, *Melilotus officinalis*, <http://www.theplantlist.org/tpl1.1/record/ild-8929>
- [37]. ITIS report, *Melilotus officinalis*, [https://www.itis.gov/servlet/SingleRpt/SingleRpt?search\\_topic=TSN&search\\_value=26150#null](https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=26150#null)
- [38]. *Melilotus officinalis*, (yellow sweet clover), <https://www.cabi.org/isc/datasheet/33697>
- [39]. U.S. National Plant Germplasm System, *Melilotus officinalis*, <https://npgsweb.ars-grin.gov/gringlobal/taxonomydetail.aspx?23989>
- [40]. Flora of Pakistan, *Melilotus officinalis*, [http://www.efloras.org/florataxon.aspx?flora\\_id=5&taxon\\_id=200012219](http://www.efloras.org/florataxon.aspx?flora_id=5&taxon_id=200012219)
- [41]. Flora of China, *Melilotus officinalis*, [http://www.efloras.org/florataxon.aspx?flora\\_id=2&taxon\\_id=200012219](http://www.efloras.org/florataxon.aspx?flora_id=2&taxon_id=200012219)
- [42]. Kirtikar KR, Basu BD. Indian medicinal plants. 2<sup>nd</sup> ed. Vol I. Dehradun, International Book Distributors 2005; 704-705.
- [43]. Bunney S. The Illustrated encyclopedia of herb. Their medicinal and culinary uses. Chancellor Press, London, UK, 1992: 190-198.
- [44]. Henriette's Herbal Homepage, *Melilotus*. <https://www.henriettes-herb.com/eclectic/kings/melilotus.html>
- [45]. Botanical.com, *Melilot*, <https://botanical.com/botanical/mgmh/m/melilo29.html>
-



- [46]. Sheikh NA and Desai TR. Phyto-physicochemical and high performance thin layer chromatography investigation of *Melilotus officinalis* Linn. International Journal of Green Pharmacy 2017; 11 (2): S285-S291.
- [47]. Tang CN. Study on the extraction process of total flavonoids from *Melilotus officinalis* medicinal plant. J Anhui Agric Sci 2012;3:23-25.
- [48]. Yang J, Wang LL and Zhang TJ. Research progress on chemical constituents in plants of *Melilotus* Linn. and their pharmacological activities. Chin Tradit Herb Drugs 2014; 45:447-454.
- [49]. Gupta AK and Grasdalen H. A D-galacto-D-mannan from *Melilotus officinalis* seed. Carbohydr Res 1988;173:159-168.
- [50]. Anwer MS, Mohtasheem M, Azhar I, Hasan M and Bano H. Chemical constituents from *Melilotus officinalis*. J Basic App Sci 2008;4(2):89-94.
- [51]. Kovaleva AM, Grudko IV, Aleksandrov AN and Komissarenko AN. GC/MS study of the chloroform fraction of *Melilotus officinalis*. Chem Nat Comp 2009; 45: 585-586.
- [52]. Gudzenko AV and Vinogradov BA. Chemical composition of the essential oil from *Melilotus officinalis* (L.) Pall. World Applied Sciences Journal 2014;29 (2): 171-172.
- [53]. Al boudi H, Daood N and Mayla LM. Study of the main components of the organic matter extracted from the leaves of Syrian *Melilotus Officinal* plant using GCMS and their effects on some of pathogenic microorganisms. Tishreen University Journal for Research and Scientific Studies - Basic Sciences Series 2018; 40(5): 163-177.
- [54]. Udayama M, Kinjo J, Yoshida N and Nohara T. A new oleanene glucuronide having a branched-chain sugar from *Melilotus officinalis*. Chem Pharm Bull (Tokyo) 1998; 46(3): 526-527.
- [55]. Kang SS, Lim CH and Lee SY. Soyasapogenols B and E from *Melilotus officinalis*. Arch Pharm Res 1987; 10: 9. <https://doi.org/10.1007/BF02855614>
- [56]. Liu YT, Gong PH, XiaoFQ, Shao S, Zhao DQ, Yan MM and Yang XW. Chemical constituents and antioxidant, anti-inflammatory and anti-tumor activities of *Melilotus officinalis* (Linn.) Pall. Molecules 2018; 23(2): 271.
- [57]. Molnar M, Jerkovic I, Suknovic D, Rajs BB, Aladic K, Šubaric D and Jokic S. Screening of six medicinal plant extracts obtained by two conventional methods and supercritical CO<sub>2</sub> extraction targeted on coumarin content, 2,2-diphenyl-1-picrylhydrazyl radical scavenging capacity and total phenols content. Molecules 2017; 22: 348; doi:10.3390/molecules22030348
- [58]. Safapour AR, Kaviyani F, Sepehrimanesh M, Ahmadi N, Hosseinabadi OK, Tanideh N and Showraki N. Antioxidant and anti-inflammatory effects of gel and aqueous extract of *Melilotus officinalis* L. in induced ulcerative colitis: A *Rattus norvegicus* model. Ann Colorectal Res 2015; 3(2): e29511. doi: 10.17795/acr-29511
- [59]. Mladenović KG, Muruzović MZ, Stefanović OD, Vasić SM, Ljiljana and Čomić R. Antimicrobial, antioxidant and antibiofilm activity of extracts of *Melilotus officinalis* (L.) pall. The Journal of Animal & Plant Sciences 2016; 26(5): 1436-1444.
- [60]. Bunney S. The illustrated encyclopedia of herb. Their medicinal and culinary uses. Chancellor Press, London,1992:190.
- [61]. Bruneton J. Pharmacognosie, phytochimie, plants medicinales. Tec et Doc, Paris 1999: 263-265.
- [62]. Karakas FP, Yildirim A and Turker A. Biological screening of various medicinal plant extracts for antibacterial and antitumor activities. Turk J Biol 2012;36:641-652.
- [63]. Nacsá-Farkas E, Pauliuc I, Krisch J and Vagvolgyi C. Anticandidal effect of the extracts from *Melilotus officinalis* and *Aristolochia clematidis*. Review on Agriculture and Rural Development 2013; 2(1): 473-477.
- [64]. Nasser NM, Al-Araji M and Al-Ani WMK. Antifungal activity of *Mellilotus officinalis* of Iraq. Journal of Chemical and Pharmaceutical Research 2014; 6(11): 611-617.
- [65]. Nacsá-Farkas E, Kerekes E, Kerekes EB, Krisch J, Roxana P, Vlad DC, Ivan P and Vágvolgyi C. Antifungal effect of selected European herbs against *Candida albicans* and emerging pathogenic non-albicans *Candida* species. Acta Biol Szeged 2014; 58(1):61-64.
- [66]. Pastura G, Mesiti M, Saitta M, Romeo D, Settineri N, Maisano R, Petix M and Giudice A. Lymphedema of the upper extremity in patients operated for carcinoma of the breast: clinical experience with coumarinic extract from *Melilotus officinalis*. Clin Ter 1999; 150(6): 403-408.
- [67]. Pastorino G, Marchetti C, Borghesa B, Cornara L, Ribulla S, Burlando B. Biological activities of the legume crops *Melilotus officinalis* and *Lespedeza capitata* for skin care and pharmaceutical applications. Industrial Crops and Products 2017; 96:158-164.
- [68]. Tanideh N, Safa O, Kheradmand S, Zarshenas MM, Mokhtari M, Hosseinabadi OK, Seddighi A, Jamshidzadeh A, Yeganeh BS, Omid M and Daneshi S. Induced third-degree burn in rat: Healing by *Melilotus officinalis* extract as medicinal plant. Trends in Pharmaceutical Sciences 2018; 4(1): 33-40.

- [69]. Nishikawa M, Yamashita A, Ando K and Mitsuhiro S. The suppressive effect of melilotus extract on the thermal edema of rats. *Nihon Yakurigaku Zasshi* 1983; 81(3): 193-209.
- [70]. Hong ND, Won DH and Kim NJ. Pharmacological studies on *Melilotus officinalis* extract. *Korean Journal of Pharmacognosy* 1983; 14(2): 51-59.
- [71]. Anwer MS, Shamin S, Ahmed S, Hasan MM and Azhar I. Hypotensive activity of *Melilotus officinalis* (L.) Pallas. *European Journal of Medicine, Series B* 2015; 3(2): 80-85.
- [72]. Momen Heravi MD, Daneshmehr S and Morsali A. Antioxidant activity of sage (*Salvia officinalis*), red cabbage (*Brassica oleracea*), walnut leaf (*Juglans regia* L.), yellow sweet clover (*Melilotus officinalis*) and hawthorn (*Crataegus oxyacantha*) at different temperatures. *Journal of Herbal Drugs* 2014; 5(2):77-83.
- [73]. Tanideh N, Bahrani M, Khoshnood-Mansoorkhani MJ, Mehrabani D, Firoozi D, Koochi-Hosseinabadi O and Iraj A. Evaluating the effect of *Melilotus officinalis* L. aqueous extracts on healing of acetic acid-induced ulcerative colitis in male rats. *Annals of Colorectal Research* 2016; 4(4): e42856
- [74]. Braga PC, Sasso MD, Lattuada N, Marabini L, Calò R, Antonacci R, Bertelli A, Falchi M and Verducci P. Antioxidant activity of *Melilotus officinalis* extract investigated by means of the radical scavenging activity, the chemiluminescence of human neutrophil bursts and lipoperoxidation assay. *Journal of Medicinal Plants Research* 2013; 7(7): 358-365.
- [75]. Alamgeer, Nasir Z, Qaisar MN, Uttra AM, Ahsan H, Khan KU, Khan IU, Saleem M, Khadijai, Asif H, Sharif A, Younis W and Naz H. Evaluation of hepatoprotective activity of *Melilomus officinalis* L. against paracetamol and carbon tetrachloride induced hepatic injury in mice. *Acta Pol Pharm* 2017;74(3):903-909.
- [76]. Sheikh NA and Desai T. Evaluation of hepatoprotective and antioxidant potential of *Melilotus officinalis* on iron dextran induced hepatotoxicity in Sprague Dawley rats. Conference: International conference on research and entrepreneurship, At: Rajkot 360020 Gujarat, India 2016.
- [77]. Zhao GC, Yuan YL, Chai FR and Ji FJ. Effect of *Melilotus officinalis* extract on the apoptosis of brain tissues by altering cerebral thrombosis and inflammatory mediators in acute cerebral ischemia. *Biomed Pharmacother* 2017;89:1346-1352.
- [78]. Kaur S, Sharma A and Bedi PMS. Evaluation of anxiolytic effect of *Melilotus officinalis* extracts in mice. *Asian Journal of Pharmaceutical and Clinical Research* 2017;10(6):396-399.
- [79]. Bazazzadegan N, Dehghan Shasaltaneh M, Saliminejad K, Kamali K, Banan M and Khorram Khorshid HR. The effects of *Melilotus officinalis* extract on expression of *Daxx*, *Nfkb* and *Vegf* genes in the streptozotocin-induced rat model of sporadic Alzheimer's disease. *Avicenna J Med Biotechnol* 2017;9(3):133-137.
- [80]. Sheikh NA, Desai TR and Tirgar PR. Investigation into iron chelating and antioxidant potential of *Melilotus officinalis* in iron dextran induced iron overloaded Sprague Dawley rat model. *Drug Res (Stuttg)* 2016;66(12):618-627.
- [81]. Hashim FJ, Hussain SM and Muayad Shawkat S. Separation, Characterization and anticoagulant activity of coumarin and its derivatives extracted from *Melilotus officinalis*. *Biosci Biotech Res Asia* 2017; 14(1): 13-23.
- [82]. Pleșca-Manea L, Pârnu AE, Pârnu M, Taămaș M, Buia R and Puia M. Effects of *Melilotus officinalis* on acute inflammation. *Phytother Res* 2002;16(4):316-319.
- [83]. Liu MW, Su MX, Wang YHa and Qian CY. Effect of Melilotus extract on lung injury via the upregulation of tumor necrosis factor- $\alpha$ -induced protein-8-like 2 in septic mice. *Mol Med Rep* 2015;11(3):1675-1684.
- [84]. Forte R, Cennamo G, Finelli ML, Bonavolontà P, de Crecchio G and Greco GM. Combination of flavonoids with *Centella asiatica* and *Melilotus* for diabetic cystoid macular edema without macular thickening. *J Ocul Pharmacol Ther* 2011;27(2):109-113.
- [85]. Zangiabadi N, Mohtashami H, Hojatipour M, Jafari M, Asadi-Shekaari M and Shabani M. The effect of angipars on diabetic neuropathy in STZ-induced diabetic male rats: A study on behavioral, electrophysiological, sciatic histological and ultrastructural Indices. Hindawi Publishing Corporation, *The Scientific World Journal* 2014, <http://dx.doi.org/10.1155/2014/721547>
- [86]. Heshmat R, Mohammad K, Mohajeri Tehrani MR, *et al.* Assessment of maximum tolerated dose of a new herbal drug, semelil (angipars) in patients with diabetic foot ulcer: A phase I clinical trial. *Daru* 2008;16(1):25-30.
- [87]. Shamimi Nouri K, Karimian R, Nasli E, *et al.* Topical application of semelil (angipars) in treatment of pressure ulcers: A randomized clinical trial. *Daru* 2008; 16(1): 54–57.
- [88]. Abdollahi M, Farzamfar B, Salari P, Khorram Khorshid HR, Larijani B, Farhadi M, *et al.* Evaluation of acute and sub-chronic toxicity of semelil (angipars), a new phytotherapeutic drug for wound healing in rodents. *Daru J Pharm Sci* 2008;16(Suppl 1):7-14.

- [89]. Asadi-Shekaari M, Eftekhari Vaghefi H, Talakoub A and Khorram Khorshid HR. Effects of semelil (angipars) on focal cerebral ischemia in male rats. *Daru* 2010; 18:265-269.
- [90]. Cataldi A, Gasbarro V, Viaggi R, Soverini R, Gresta E and Mascoli F. Effectiveness of the combination of alpha tocopherol, rutin, melilotus, and centella asiatica in the treatment of patients with chronic venous insufficiency. *Minerva Cardioangiol* 2001; 49(2): 159-163.
- [91]. Radostits QM, Searcy GP, and Mitchall KG. Moldy sweet clover poisoning in cattle. *Can Vet J* 1980; 21(5): 155-158.
- [92]. Baumann CA, Field JB, Overman RS and Link KP. Studies on the hemorrhagic sweet clover disease. *J Biol Chem* 1942; 146: 7-14.
- [93]. Stegelmeier BL. Poisonous Plant Research Laboratory, USDA-ARS. <https://www.msdsvetmanual.com/toxicology/sweet-clover-poisoning/overview-of-sweet-clover-poisoning>
- [94]. Puschner B, Galey FD, Holstege DH and Palazoglu M. Sweet clover poisoning in dairy cattle in California. *J Am Vet Med Assoc* 1998; 212(6): 857-859.

Ali Esmail Al-Snafi. "Chemical Constituents and Pharmacological Effects of Melilotus Officinalis- A Review." *IOSR Journal of Pharmacy (IOSRPHR)*, 10(1), 2020, pp. 26-36.